Global Blood Therapeutics Announces Appointment of Tricia Suvari as Chief Legal Officer
12 October 2016 - 11:00PM
Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), a
biopharmaceutical company developing novel therapeutics for the
treatment of grievous blood-based disorders with significant unmet
needs, today announced the expansion of its management team with
the appointment of Tricia Suvari as chief legal officer.
“Tricia brings a wealth of experience managing the complex legal
and business situations that arise in rapidly growing
biopharmaceutical companies,” said Ted W. Love, M.D., president and
chief executive officer of GBT. “Her knowledge and expertise
managing business development opportunities, financings, and
commercial compliance responsibilities will serve well in this role
as we continue to grow as a company.”
Ms. Suvari has approximately 20 years of experience in the life
sciences industry. She previously served in several senior roles at
CV Therapeutics, ultimately as senior vice president, general
counsel and chief compliance officer. At CV Therapeutics, she led
the in-house legal team as the company transitioned from an
R&D-stage company to a commercial-stage company with marketed
products in the US and EU and multiple partnering arrangements.
Prior to CV Therapeutics, she served as senior counsel at
Genentech, where she completed many complex business development
and licensing transactions and advised on legal compliance for
several commercial products. She has also served as an independent
consultant, supporting biopharmaceutical companies ranging from
early-stage private companies to public companies. Most recently
before joining GBT, Ms. Suvari served as a vice president and
general counsel at the non-profit Peninsula Open Space Trust, where
she led the land transactions team responsible for negotiating,
structuring and funding complex conservation-oriented real estate
transactions. Ms. Suvari earned her Bachelor of Sciences degree in
Geology and Geophysics from Yale University and her J.D. degree
from Harvard Law School.
About Global Blood
Therapeutics Global Blood Therapeutics, Inc. is
a clinical-stage biopharmaceutical company dedicated to
discovering, developing and commercializing novel therapeutics to
treat grievous blood-based disorders with significant unmet
need. GBT is developing its lead product candidate, GBT440, as
an oral, once-daily therapy for sickle cell disease (SCD) and is
currently evaluating GBT440 in a Phase 1/2 study in both healthy
subjects and adults with SCD and a Phase 2a study in adolescents
with SCD. GBT is also investigating GBT440 for the treatment of
hypoxemic pulmonary disorders in an ongoing Phase 2a study in
patients with idiopathic pulmonary fibrosis. Additionally, GBT is
also engaged in research and development activities with an oral
kallikrein inhibitor for the prevention of hereditary angioedema
attacks. To learn more, please
visit: www.globalbloodtx.com.
Contact Information:
Myesha Edwards (investors)
Global Blood Therapeutics
650-351-4730
investor@globalbloodtx.com
Julie Normart (media)
BrewLife
415-946-1087
media@globalbloodtx.com
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Apr 2024 to May 2024
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Global Blood Therapeutics Inc (NASDAQ): 0 recent articles
More News Articles